Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium
GYNECOLOGIC ONCOLOGY(2023)
摘要
Patients with endometrial cancer are eligible for checkpoint inhibitor therapy based on their molecular signature, including mismatch repair deficiency (dMMR), microsatellite instability (MSI-H), and high tumor mutation burden (TMB H). The objective of this study was to compare the clinical characteristics and outcomes of patients who were found to be TMB H, MSI-H/dMMR, both, or neither.
更多查看译文
关键词
high tumor mutational burden,high microsatellite stability,repair deficiency,clinical outcomes patients,cancer,multi-institutional
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要